Treatment of chemotherapy-induced nausea and vomiting

被引：10
作者：
Inrhaoun H. [1 ]
Kullmann T. [2 ]
Elghissassi I. [1 ]
Mrabti H. [1 ]
Errihani H. [1 ]
机构：
[1] Department of Medical Oncology, National Institute of Oncology, Rabat
[2] Department of Medical Oncology, Saint Louis Hospital, Paris
来源：
Journal of Gastrointestinal Cancer | 2012年 / 43卷 / 4期
关键词：
Antiemetic; Chemotherapy; Nausea-vomiting;
D O I：
10.1007/s12029-012-9401-6
中图分类号：
学科分类号：
摘要：
Background: Recent improvements in medical oncology include both development of anticancer and supportive therapy. Serotonin receptor antagonists were introduced in clinical practice 20 years ago. Since then, the prevention and treatment of chemotherapy-induced nausea and vomiting allows continuing efficacious chemotherapy that earlier had to be stopped sometimes for intolerance. Aim: This anniversary review summarises the current antiemetic arsenal focussing on the most potent antiemetic drugs such as serotonin and substance P receptor antagonists. Result: Antiemetic treatment improves quality of life under chemotherapy and contributes to the survival benefit as well. In spite of the use of these new drugs, a significant number of patients still experience nausea and vomiting. Special complications like delayed emesis can be alleviated by combination therapies. Conclusion: Prevention and optimal management of chemotherapy-induced nausea and vomiting should be a goal for most patients receiving emetogenic chemotherapy. © 2012 Springer Science+Business Media, LLC.
引用
收藏
页码：541 / 546
页数：5
相关论文
共 43 条
  • [1] Glare P.A., Danwoodie D., Drugs, 68, 18, pp. 2575-2590, (2008)
  • [2] Herrstedt J., Nat Clin Pract Oncol, 5, 1, pp. 32-43, (2008)
  • [3] Baines M.J., ABC of palliative care. Nausea, vomiting, and intestinal obstruction, BMJ, 315, 7116, pp. 1148-1150, (1997)
  • [4] Mannix K.A., Palliation of nausea and vomiting, CME Can Med, 1, 1, pp. 18-22, (2002)
  • [5] Grunberg S.M., Hesketh P.J., Control of chemotherapy-induced emesis, N Engl J Med, 329, pp. 1790-1796
  • [6] Cubeddu L.X., Oncology, 53, SUPPL. 1, pp. 18-25, (1996)
  • [7] Hesketh P.J., Gralla R.J., Webb R.T., Ueno W., Delprete S., Bachinsky M.E., Et al., Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis, J Clin Oncol, 17, pp. 338-343, (1999)
  • [8] Hesketh P.J., Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting, Support Care Cancer, 9, 5, pp. 350-354, (2001)
  • [9] Markman M., Progress in preventing chemotherapy-induced nausea and vomiting, Cleve Clin J Med, 69, 8, pp. 609-617, (2002)
  • [10] Jordan K., Schmoll H.J., Aapro M.S., Comparative activity of antiemetic drugs, Crit Rev Oncol Hematol, 61, pp. 162-175, (2007)
12345